<DOC>
	<DOCNO>NCT03005067</DOCNO>
	<brief_summary>This study conduct adult participant symptoms common cold assess 1146A nasal spray reduces severity symptom common cold compare placebo . The study also evaluate safety 1146A compare placebo .</brief_summary>
	<brief_title>To Evaluate Efficacy Safety 1146A Nasal Spray Adult Participants With Symptoms Common Cold</brief_title>
	<detailed_description>This multi-center , randomize , parallel-group , double blind , 2-arm , placebo control study evaluate efficacy safety 1146A adult participant symptomatic common cold outpatient setting .</detailed_description>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Carbopol 940</mesh_term>
	<criteria>Demonstrates understand study procedure , restriction willingness participate evidenced voluntary write informed consent receive sign date copy inform consent form . Aged 18 75 year inclusive . Male female . Good general mental health , opinion Investigator medically qualify designee clinically significant relevant abnormality medical history upon physical Investigatorled nasal examination . Females childbearing potential , opinion Investigator , practice reliable method contraception . Adequate contraception define abstinence , oral contraceptive , either combined progestogen alone OR injectable progestogen OR implant levonorgestrel OR estrogenic vaginal ring OR percutaneous contraceptive patch OR intrauterine device intrauterine system OR double barrier method ( condom occlusive cap ( diaphragm cervical vault cap ) plus spermicidal agent ( foam , gel , film , cream , suppository ) ) OR male partner sterilization prior female participant 's entry study , male sole partner participant . Investigator confirm diagnosis symptomatic common cold onset le 48 hour prior randomization . Symptomatic common cold define TSS &gt; 9 AND score &gt; 1 least one follow symptom : sore throat , runny nose , block nose . Women positive urine pregnancy test . Women breastfeed . During entire study ( Screening last participant visit ) : A . Participant use medication therapy could interfere study evaluation proper washout period medication therapy anticipate require concomitant intranasal medication period time throughout study . B. Nasal disease ( ) likely affect deposition intranasal medication , chronic sinusitis , rhinitis medicamentosa , clinically significant polyposis , clinically significant nasal structural abnormality . C. Nasal surgery sinus surgery within previous year . D. Any condition prohibits participant actuate nasal spray device ( severe rheumatoid arthritis ; deform hand finger ; miss finger ) . E. Clinically relevant abnormal physical finding , opinion Investigator sponsor 's medical monitor , would interfere objective study may preclude compliance study procedure . F. Uncontrolled cardiovascular , pulmonary , renal , hepatic , gastrointestinal , hematological , endocrine , metabolic , autoimmune , neurological , psychiatric disease screen would interfere study opinion Investigator . G. Participants seasonal allergic rhinitis randomization occur expect allergy season perennial allergic rhinitis . H. Severe COPD , persistent asthma , recent COPD/asthma exacerbation . I . An inability comprehend satisfactorily use measurement instrument determine study site staff screen . J . Participants fever &gt; 38°C ( 100.4°F ) . K. Frequent use analgesic ( i.e . take analgesic pain headache pain muscle/joints least 1 dose per week average past 6 month ) . Known suspected intolerance hypersensitivity study medication , excipients investigational device material medication similar chemical class , history drug hypersensitivity significant allergic diathesis could affect study participation know suspected contraindication , include history allergy photosensitivity study medication/s . Participation another clinical study ( include cosmetic study ) receipt investigational drug within 30 day screen visit 5 halflives enrollment , whichever longer previous participation study ( i.e . participant rescreened randomize ) . Recent history ( within last 5 year ) alcohol substance abuse positive urine drug screen . An employee sponsor study sit member immediate family person directly indirectly involved execution protocol , include employee contract research organization ( CRO ) person relate . On nasal examination Investigator , presence nasal disease likely affect deposition intranasal treatment superficial moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation screen visit . Participants difficulty use nasal spray applicator , `` vulnerable '' individual ( defined IRB e.g . incarcerated person ) condition identify protocol opinion Investigator would confound evaluation interpretation study data may put participant risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>